Top

advancing

the vision to heal

The potential to simulate natural healing

 

Noveome is advancing its ST266 platform biologic, a first-of-its-kind, multi-targeted secretome containing hundreds of biologically active proteins and other factors crucial to neuroprotection, the modulation of inflammation, cell recovery and healing. We believe this novel platform biologic holds significant clinical potential across a range of important underserved conditions in ophthalmology, neurology, dermatology—and beyond.

exciting science

Learn more about ST266 and its unique and powerful healing potential.

advancing pipeline

Explore our portfolio covering a range of important ophthalmic indications.

rewarding careers

Join a passionate, diverse team dedicated to making a positive difference in patients’ lives.

making news

August 31, 2020

PITTSBURGH – August 31, 2020 – Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion…

June 12, 2020

Noveome Biotherapeutics Announces Positive Data for Phase 2 Clinical Trial of ST266 in Patients with Persistent Corneal Epithelial Defects

May 12, 2020

Singota Solutions Collaborates with Noveome Biotherapeutics, Inc. to Manufacture Promising Therapy to Treat Severe Condition in People Infected with COVID-19